British regulators from the National Institute for Health and Clinical Excellence, or NICE, decided on Wednesday not to recommend Novartis's (NYSE:NVS) cancer drug Jakavi for treatment of myelofibrosis, a type of rare blood cancer affecting less than one in 100,000 people each year in Britain.
In a silver lining for Novartis, NICE did note that Jakavi showed effectiveness in treating symptoms of myelofibrosis, such as an enlarged spleen and fatigue, and that the drug could offer a survival benefit to patients. However, regulators wouldn't green light the drug as it "could not be considered a cost-effective use of NHS resources" compared to other therapies.
NICE's Health Technology Evaluation Centre Director, Carole Longson, commented on the cost issue in NICE's press statement, saying:
It is disappointing not to be able to recommend this new treatment in our preliminary recommendations, but in order to do this we have to be sure that the treatment is both clinically and cost effective, because money has to be diverted from elsewhere in the health service to pay for it.
The recommendation made by NICE is only guidance, and a final decision on the drug won't come until later this year. Regulators will consult with Novartis before then. Jakavi is already approved in the E.U. to treat myelofibrosis.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Philip Morris International Inc. Advanced 15.5% in 2017
After a half-decade of disappointing performance, there's a possible catalyst in Philip Morris' future.
Why McDonald's Stock Gained 41.4% in 2017
McDonald's hasn't looked this good in years.
Microsoft Earnings: Will Strong Growth Persist?
Can strong growth in cloud services and Office 365 help revenue rise nicely in Q2?